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Previous studies based on low oxygen concentrations in the incubation atmosphere revealed that metabolic factors govern the
maintenance of normal hematopoietic or leukemic stem cells (HSC and LSC). The physiological oxygen concentration in tissues
ranges between 0.1 and 5.0%. Stem cell niches (SCN) are placed in tissue areas at the lower end of this range (“hypoxic” SCN),
to which stem cells are metabolically adapted and where they are selectively hosted. The data reported here indicated that driver
oncogenic proteins of several leukemias are suppressed following cell incubation at oxygen concentration compatible with SCN
physiology. This suppression is likely to represent a key positive regulator of LSC survival and maintenance (self-renewal)
within the SCN. On the other hand, LSC committed to differentiation, unable to stand suppression because of addiction to
oncogenic signalling, would be unfit to home in SCN. The loss of oncogene addiction in SCN-adapted LSC has a consequence of
crucial practical relevance: the refractoriness to inhibitors of the biological activity of oncogenic protein due to the lack of their
molecular target. Thus, LSC hosted in SCN are suited to sustain the long-termmaintenance of therapy-resistantminimal residual disease.
1. Introduction
Most stem cell studies, and definitely all of the earliest
ones, were carried out using hematopoiesis as a model of
tissue regeneration. Likewise, hypotheses to describe the
tissue environment where normal stem cells are main-
tained were developed within a hematological context.
Schofield organized this issue conceptually in 1978, putting
forward the “stem cell niche” (SCN) model [1] to define
bone marrow (BM) sites dedicated to the maintenance of
hematopoietic stem cells (HSC). The model predicted that
this maintenance is achieved by preventing HSC commit-
ment to differentiation. In other words, if HSC proliferate
within the SCN environment, they would do without losing
stem cell potential, that is, undergoing the so-called
“self-renewal,” which is a defining feature of stem cells.
The SCN model was supported by experimental findings
indicating that HSC and less immature hematopoietic
progenitor cells (HPC) are compartmentalized rather than
randomly distributed in BM, HSC being located preferen-
tially close to the bone surface and HSC/HPC instead in
proximity of the central sinus [2–5]. Hematopoietic cells
homing in BM after exogenous transplantation follow a
similar compartmentalization pattern [6]. The definition
of the relationship between “endosteal SCN,” where
HSC are maintained, and “vascular SCN,” where HSC
commitment to differentiation and HPC clonal expansion
are driven, was completed much later [7, 8]. Hereafter,
the acronym SCN is used to indicate SCN where HSC
are maintained.
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That metabolic factors take part in the regulation of
hematopoiesis emerged from studies indicating that low oxy-
gen concentrations in the incubation atmosphere enhance
the yield of hematopoietic cultures [9–15]. The issue was
deepened in the early 1990s in our laboratory using 1%
oxygen to culture murine BM cells. In 1% oxygen, HSC
maintenance was enhanced while the overall hematopoietic
output was reduced. HPC were indeed suppressed, the more
severely the lower their hierarchical level. These studies pro-
vided the first mechanistic implementation of the Schofield’s
SCN model and led to putting forward the hypothesis of a
“hypoxic SCN” dedicated to hosting and preserving HSC
selectively from HPC [16]. The effects of low oxygen were
later confirmed, by us and others, for human hemato-
poiesis and long-term-repopulating HSC [17–21]. When
we addressed directly the role of low oxygen in modulating
self-renewal, we found that one replication cycle in cultures
incubated in 1% oxygen boosts stem cell potential. Such an
effect is lost when cycling is sustained for more than one cycle
and does not occur in air or in the presence of interleukin-3
(IL-3). This indicates that HSC self-renewal occurs immedi-
ately after HSC rescue from quiescence to cycling, provided
this happens in low oxygen, which therefore appears as a
crucial factor to spare stem cell potential. Thus, low oxygen
maintains HSC in a state where proliferation is allowed, but
not commitment to differentiation. The latter is instead typ-
ically driven when proliferation is extensively stimulated,
such as in the presence of IL-3 [22].
Although tissue areas where stem cell potential is
maintained are commonly referred to as “hypoxic SCN,”
low-oxygen tensions represent a physiological feature of
SCN. Indeed, while the nonphysiological sea-level atmo-
spheric oxygen concentration (20-21%) is considered a phys-
iological standard (“normoxia”) for cell culture incubation,
oxygen tensions corresponding to 0.1–5% concentration
actually characterize the microenvironment of a number of
different tissues. Thus, close to the lower end of this range,
oxygen tensions are normoxic for HSC but hypoxic for
HPC and the bulk of hematopoietic cell population. This
issue is reviewed elsewhere [23–25].
To take advantage of their selective homing in tissue
areas at the lowest oxygen tensions, HSC need a complex
pattern of metabolic adaptation which is not shared by
HPC. It is worth noting here that, in keeping with what
summarized above, the term “adaptation” is commonly used
with a reverse meaning. The term refers in fact to the capacity
of cells to home at the lower oxygen tensions actually found
in tissues (“adaptation to hypoxia”), instead of defining the
conditions enabling cells to stand the nonphysiologically
elevated oxygen concentrations used for cell culture (“adap-
tation to hyperoxia”) [25]. When it comes to defining the
metabolic peculiarity of HSC with respect to HPC, one must
specify that this peculiarity does not simply consist of the
compatibility with tissue “hypoxia,” as either HSC or HPC
exhibit a “hypoxic” metabolic profile [26]. Rather, as men-
tioned above, HSC, different from HPC, are capable to stand
the lowest physiological oxygen tensions (0.1–1%, referred to
as very low oxygen) and for extended times. The regulative
role of hypoxia-inducible factor-α (HIFα) signalling on
hematopoiesis needs to be considered within this context.
HIF1α upregulation via transcriptional activation and/or
protein stabilization is known as the key driver of cell “adap-
tation to hypoxia.” However, as its stabilization threshold is
2% oxygen or even higher [27], HIF1α alone cannot select
HSC from HPC or confer upon HSC all the features enabling
their exclusive homing in the very low-oxygen SCN. In other
words, HIF1α stabilization is necessary but not sufficient
condition for HSC maintenance. HIF1α activity is indeed
required for the maintenance of HSC as well as leukemia
stem cells (LSC) of chronic myeloid leukemia (CML)
[28, 29]. Thus, while the overall “adaptation to hypoxia”
requires HIF1α upregulation, enhanced glycolysis and
reduced mitochondrial/respiratory activity, only a small
minority of hypoxia-adapted cells is capable to stand the very
low-oxygen tensions typical of SCN [30]. The characteriza-
tion of this cell subset is of course of great interest, especially
in oncological settings.
The use of 0.1% oxygen in the incubation atmosphere
of leukemia cell populations led us to detecting a crucial
feature of the SCN-adapted LSC subset [31, 32]. In an
environment where all cells are subjected to HIF1α-driven
metabolic adaptations (see above), we found that only a
minority of CML or murine erythroleukemia (MEL) cells
persists throughout extended incubation times. In these
cells, while stem cell potential is maintained, the oncogenic
protein responsible for disease is lost (“oncogene suppres-
sion”) [33, 34]. In the case of CML, this loss was found to
occur when the shortage of glucose complicates that of
oxygen [35]. This points to the existence of a leukemia cell
subset combining the adaptation to energy shortage with
the suppression of oncogenic signals. Such a combination
is likely to be a key factor enabling this cell subset to survive
within the selective SCN environment. A crucial by-product
of oncogene suppression in CML is that SCN-adapted cells
are refractory to the tyrosine kinase inhibitors (TKi) which
target the constitutive enzymatic activity of the BCR/Abl
oncogenic protein responsible for disease [33, 35], in keep-
ing with findings obtained in other laboratories [36–38].
Refractoriness to therapy due to the fact that its molecular
target is suppressed in some surviving cells, LSC in partic-
ular, possibly represents the most straightforward expla-
nation of the long-term persistence of therapy-resistant
minimal residual disease (MRD) of CML [31, 32]. The
data reported in this paper indicated that oncogenic proteins
and signals are suppressed in several different leukemias
incubated at very low-oxygen concentration. The relevance
of this phenomenon as a general aspect of leukemia cell adap-
tation to severe energy restriction is discussed.
2. Materials and Methods
2.1. Cells and Culture Conditions. K562 and KCL22
(human CML), NB4 (human acute promyelocytic leukemia),
Kasumi-1 (human acute myeloid leukemia), and MEL cell
lines were cultured in RPMI 1640 (containing 2 g/l of D-
glucose) supplemented with 10% foetal bovine serum,
50 units/ml penicillin, 50mg/ml streptomycin, and 2mM/l-
glutamine (all fromEuroClone, Paignton, UK). Exponentially
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growing cells were plated at 3× 105 or 3× 104 cells/ml and
incubated at 37°C in water-saturated atmosphere contain-
ing 0.1% O₂, 94.9% N₂, and 5% CO₂ in an anaerobic
workstation (Concept 400, Baker Ruskinn, York Road, or
DG250, Don Whitley Scientific, Shipley, Bridgend, UK)
or in normoxia (21% O₂ and 5% CO₂) in a conventional
cell culture incubator. Cell viability was measured by try-
pan blue (#F-7378, Sigma-Aldrich, St. Louis, MO, USA)
exclusion test.
2.2. Protein Extraction and Western Blotting. Cells were
lysed in Laemmli buffer and protein concentration was
determined by the BCAmethod (Pierce™ BCA Protein Assay
Kit; Thermo Fisher Scientific, Waltham, MA, USA).
Extracted proteins were subjected to SDS-PAGE and
transferred onto polyvinylidene fluoride membranes
(Merck-Millipore, Billerica, MA, USA) by electroblotting.
Membranes were blocked in a 1 : 1 dilution of Odyssey block-
ing buffer (OBB; LI-COR® Biosciences, Lincoln, NE, USA)
with PBS and then incubated at 4°C overnight with primary
antibody in a 1 : 1 dilution of OBB with PBS-0.1% Tween
20 (T-PBS). Primary antibodies used were rabbit poly-
clonal anti-pCRKL (#3181) from Cell Signaling Technology
(Danvers, MA, USA); rabbit polyclonal anti-c-Abl (sc-131),
anti-erythropoietin-receptor (EPo-R; sc-697) and anti-
ERK1 (sc-93), mouse monoclonal anti-RARα (sc-515796)
and anti-tubulin (sc-32393), and goat polyclonal anti-ETO
(sc-9737) and anti-GAPDH (sc-20357) from Santa Cruz
Biotechnology (Santa Cruz, CA, USA); rabbit polyclonal
anti-histone 4 (H4; #07-108) from Merck-Millipore; goat
anti-R-MuLV gp70 antiserum, recognizing gp55 in MEL
cells, kindly provided by Dr. Sandra Ruscetti (Laboratory of
Cancer Prevention, National Cancer Institute, Frederick,
MD, U.S.A.); and rabbit anti-ARD1, produced in Dr.
Nathalie Mazure’s laboratory. After washing with T-PBS,
membranes were incubated for 1 h at room temperature in
OBB 1 : 1 with PBS containing IRDye800CW (1 : 20000)- or
IRDye680 (1 : 30000)-conjugated secondary antibody (LI-
COR). Antibody-coated protein bands were visualized by
Odyssey Infrared Imaging System Densitometry (LI-COR
Biosciences, Lincoln, NE, USA), as previously reported [39].
2.3. Measurement of Glucose Concentration in Culture
Medium. Medium samples were harvested at the indicated
times and stored frozen at −20°C until analysis was per-
formed by the glucose hexokinase method using the ADVIA
2400 Chemistry System (Siemens, Camberley, Surrey, UK).
2.4. Statistical Analysis. Statistical analyses were performed
using Student’s t-test and GraphPad Prism software. A
p value less than 0.5 was considered statistically significant.
3. Results
The incubation of CML cell lines in atmosphere at 0.1%
O2 was paralleled by a time-dependent suppression of
BCR/Abl protein, which did not occur in cells incubated
at 21% O2 (Figures 1(a) and 1(b)), in keeping with what
was previously shown [33, 35, 40]. These findings are con-
firmed and extended here to primary CML cells explanted
from BM of a patient in blast crisis (Figure 1(c)).
Figures 1(a) and 1(b) also show that incubation in low
oxygen led to a decrease in the phosphorylated form of
CRLK, a major BCR/Abl downstream substrate used as
read-out of BCR/Abl activity. Thus, the suppression of
BCR/Abl protein abolished, as expected, its tyrosine kinase
activity. The kinetics of BCR/Abl suppression varied
depending on the cell line analysed. Indeed, in K562 cells,
BCR/Abl protein level was undetectable starting from day
3 of incubation in low oxygen (Figure 1(a), blot on the
left), while in KCL22 cells, BCR/Abl protein suppression
occurred at day 4 (Figure 1(b)).
Previous studies carried out in our laboratory revealed a
close relationship between suppression of BCR/Abl protein
in CML cells and glucose exhaustion from culture medium
[35]. These findings are confirmed and extended here by
measuring the time course of glucose concentration in
cultures of KCL22 cells and in K562 cells plated at different
concentrations (Figures 1(a) and 1(b), graphs). In the exper-
iments carried out with KCL22 cells, glucose got exhausted
between day 3 and day 4, when BCR/Abl protein expression
became undetectable (Figure 1(b)). In K562 cell cultures
where 3× 105 cells/ml were plated at time zero, glucose was
already exhausted on day 3, when BCR/Abl protein expres-
sion became undetectable (Figure 1(a), blot on the left). In
K562 cell cultures established with 3× 104 cells/ml, glucose
was still relatively high on day 7 and exhausted on day 10,
findings perfectly in keeping with those relative to BCR/Abl
protein expression (Figure 1(a), blot on the right). These data
confirmed the relationship between glucose consumption
and BCR/Abl protein suppression.
The effects of incubation at 0.1% O2 of a number of non-
CML leukemia cell lines are shown in Figure 2. MEL and
Kasumi-1 cells underwent a time-dependent suppression of
the oncogenic protein(s) driving the disease (Figures 2(a)
and 2(b)), in keeping with previous observations [34, 41].
These findings are extended here to NB4 cells (Figure 2(c)).
It is to note in particular that in MEL cells, either the gp55
protein of Friend’s virus or the EPo-R, both contributing
to oncogenic signalling in these cells, was suppressed. In
Kasumi-1 cells, the oncogenic driver AML1/ETO protein
behaved likewise. In NB4 cells, incubation in low oxygen
led to the suppression of the oncogenic driver PML/RARα,
but not the normal RARα protein; a lysate of K562 CML cells
was added to the electrophoretic run as negative control.
4. Discussion
This paper shows that incubation at very low-oxygen
tensions determines the suppression of driver oncogenic
proteins and signals in a number of leukemia cell popula-
tions, leading to hypothesizing that this suppression is a
widespread phenomenon occurring in different types of
cancers, including solid neoplasias. That the triggering of
suppression mechanism is related to the onset of severe
energy restriction rather than simply to “adaptation to
hypoxia” is supported by the fact that, in all types of leukemia
tested, oncogene suppression occurred only after 3-4 days
of incubation in very low oxygen. Consequently, the
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phenomenon cannot be simply (or directly) ascribed to
HIF1α activation, which is driven within minutes of cell
challenged with oxygen shortage. Based on the previous find-
ing that BCR/Abl suppression in low oxygen parallels the
onset of glucose shortage [35] and on the data reported here,
what we call “severe energy restriction” seems actually to con-
sist of glucose exhaustion from culture medium.
The time-dependent suppression of oncogenic proteins
we found as a widespread response of leukemia cells to incu-
bation in low oxygen needs to be discussed within the issue of
the general effects of “hypoxia” on protein expression [42].
Indeed, the ATP demand for protein synthesis under
“hypoxia” has been estimated to drop to about 7% of that
in “normoxia” [43]. This drop occurs initially at the level of
translation and later extends to transcription level [44].
Despite such a general decrease in protein synthesis, mRNA
translation continues of course for factors important for
adaptation to “hypoxia,” such as HIF-α and HIF-β, vascular
endothelial growth factor, and platelet-derived growth factor
[45]. On the other hand, we found that, in CML cells, a num-
ber of not directly hypoxia-related proteins, such as tubulin
for example, are not affected by energy shortage following
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Figure 2: Suppression of oncogenic proteins driving non-CML blood neoplasias in the course of cell “adaptation to hypoxia.” MEL (a),
Kasumi-1 (b), or NB4 (c) cells were incubated in atmosphere at 0.1% O2 and lysed at the indicated times, and total cell lysates were
subjected to immunoblotting with the indicated antibodies. GAPDH, H4, or ARD1 were detected to verify loading equalization. Migration
of molecular weight markers is indicated on the left (kDa). For each cell population, one out of three independent experiments with
similar outcome is shown.
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Figure 1: Suppression of BCR/Abl protein in CML cells undergoing “adaptation to hypoxia.” K562 cells (a), KCL22 cells (b), or blast-crisis
primary cells (c) were plated at the indicated time-zero cell concentrations and incubated in atmosphere at 0.1% or 21% O2. Cell lysates
obtained at the indicated incubation times were immunoblotted using anti-c-Abl (detecting BCR/Abl) or anti-phospho-CRKL antibodies
or, as loading equalization control, anti-GAPDH or anti-ERK1/2 antibodies; migration of molecular weight markers is indicated on the
left (kDa). One out of three independent experiments with similar outcome is shown. Glucose concentration in the medium of cultures
incubated at 0.1% O2 was measured at the indicated incubation times as described in Materials and Methods. Values are means± SD
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either oxygen or glucose deprivation [40]. However, the
relationship of downregulation of protein expression to
oxygen and glucose shortage remains to be deepened.
As briefly mentioned in the Introduction, oncogene sup-
pression under severe energy restriction most likely mirrors
the fact that this condition is incompatible with sustained
oncogenic signalling which drives commitment to clonal
expansion and differentiation. The experiments reported in
this paper did not address directly the regulation of LSC
maintenance in the function of the expression of driver
oncogenes. However, previous data obtained for some of
the cell lines used here indicate that, under conditions driv-
ing oncogene suppression, cell growth is markedly reduced
while stem cell potential is not suppressed [33–35]. In this
respect, it is worth pointing out that stabilized leukemia cell
lines are highly heterogeneous populations which comprise
a full spectrum of different functional phenotypes and
include cycling or quiescent cell subsets endowed with stem
cell potential [34]. Based on these premises, one can pro-
pose that LSC are capable in principle to survive in the
absence of oncogenic signalling and that metabolic pressure
in the low-energy SCN exploits this capacity and actually
selects LSC which have lost oncogene addiction and are
capable to stand oncogene suppression (Figure 3). On the
contrary, in LSC which do not undergo metabolic adapta-
tion, oncogene addiction is maintained, so that oncogene
suppression would result in the induction of apoptosis,
the so-called “oncogenic shock.” In other words, main-
tained oncogenic stimulation (enforcing commitment to
differentiation and clonal expansion) makes LSC unfit to
home in SCN, where they would suffer of the prevalence
of proapoptosis over prosurvival stimuli upon withdrawal
of oncogenic signalling [46–48].
The loss of oncogene addiction within the SCN implies a
de facto reversion of LSC to the normal HSC phenotype, as
long as they remain under conditions where the balance
within the regulation of LSC compartment is in favour of
the maintenance of stem cell potential rather than of com-
mitment to differentiation [48]. Revertant LSC are likely to
rely on physiological extra-/intra-cellular signals for support
of their survival and self-renewal. In other words, the loss of
oncogenic signalling in LSC should be considered function-
ally equivalent to HSC deprivation of cytokine signalling
which drives commitment to differentiation and extensive
proliferation, such as that of IL3 [22]. However, LSC adapted
to the SCN environment maintain their leukemic genetic
signature, so that they are capable, when transferred to
growth-permissive conditions outside the SCN, to regenerate
oncogenic protein-expressing/protein-dependent cells and
thereby to rescue drive to clonal expansion and relapse of
disease [33, 35, 40]. Thus, oncogene suppression is not a
genetically blocked event but a fully reversible phenotypical
adaptation, according to the “chiaroscuro stem cell” model
proposed by Quesenberry et al. in 2002 to define the rela-
tionship between the HSC and HPC phenotypes [49]. This
model may be integrated with the model, proposed by
Reya and coworkers, defining two alternative scenarios
for the generation of cancer stem cells [50], that is, the
oncogenic transformation of a normal (self-renewing) stem
cell or the staminalization (acquisition of self-renewal) of a
normal progenitor cell. Our data seem to indicate that
these two scenarios are to be considered complementary
Suppression of
oncoprotein
Stem/progenitor cell
(clonal expansion)
Induction of
metabolic adaptation
Downregulation
of proliferation
stimuli
“Oncogenic
shock”
Stem cell
(MRD)
Only stem cells adapted
to severe energy restrictions
survive in the absence of
oncogenic signalling
Survival >>>
apoptosis
Low-energy
stem cell niche
Apoptosis
>>> survival
Figure 3: Metabolic adaptation lets stem cell escape oncogene addiction and oncogenic shock. Suppression of oncogenic signalling is
necessary to prevent stimuli driving commitment to clonal expansion and differentiation from antagonizing the long-term maintenance of
stem cell properties in the SCN. Oncogene suppression puts under stress (black arrowheads/box) stem/progenitor cells committed to clonal
expansion and differentiation, which are oncogene-addicted. Thus, in the SCN, these cells would be subjected to prevalent proapoptotic
stimuli and undergo the “oncogenic shock.” On the contrary, stem cells which metabolically adapt to SCN environment become independent
of oncogene signalling (lose oncogene addiction) and escape oncogenic shock (white arrowheads/box), ensuring MRD maintenance.
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rather than alternative and to correspond, respectively, to
LSC capable or incapable to adapt to and home in SCN.
A crucial, and of high practical relevance, consequence
of oncogene suppression is that SCN-adapted LSC which
reverted to a normal HSC phenotype exhibit complete
refractoriness to inhibitors of the biological activity of
the oncogenic protein, due to the lack of their molecular
target [31, 32]. The combination of refractoriness to therapy
with long-term persistence in tissues makes SCN-adapted
LSC the best candidates to sustain MRD in vivo. As far as
CML is concerned, the presence of these LSC is probably
the main reason of the failure of BCR/Abl-targeting TKi
to eradicate LSC, suppress MRD, and prevent relapse of
disease [51]. In this scenario, it is predictable that even
next-generation TKi will be equally ineffective, as we already
observed in vitro (manuscript submitted). All above urges to
investigate on the mechanisms of LSC adaptation to severe
oxygen and nutrient shortage in view of the design of thera-
peutic strategies directed to eradicate, rather than to control,
leukemia. However, a drawback preventing a useful applica-
tion of such strategies is represented by the revertant nature
of metabolically adapted LSC, which implies the risk of seri-
ously damaging the HSC pool while trying to eradicate LSC.
In this respect, current therapeutic approaches directed to
suppress oncogene-addicted leukemia/cancer cells commit-
ted to clonal expansion and differentiation while tolerating
the maintenance of LSC self-renewal at the subclinical level
may turn out to represent a safer scenario.
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